Efficacy and Safety of Oxymetazoline 1% Cream for the Treatment of Mild to Moderate Facial Rosacea
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.16782 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Fatemeh Sajdeh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Facial Dermatoses, Oxymetazoline, Rosacea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences.
Abstract (Originalsprache)
Introduction
Rosacea is a common skin condition that affects the physical and mental health of the patient. The objective of this study was to evaluate the efficacy and safety of oxymetazoline 1% cream, a specific α1A‐adrenoceptor agonist, for the treatment of mild to moderate facial rosacea.
Methods
In phase II of the before–after study, 15 patients with mild to moderate rosacea were enrolled and treated with oxymetazoline 1% cream twice daily for 4 weeks. The clinician's erythema assessment (CEA) and patient's self‐assessment (PSA), as well as the skin biometric parameters (transepidermal water loss, sebum, stratum corneum hydration, temperature, erythema, melanin, and pH), dermal and epidermal thickness and echo‐density, and capillaroscopic pattern were assessed and compared before and after treatment. p ‐Value < 0.05 was considered significant.
Results
CEA and PSA indexes decreased significantly 2 and 4 weeks after the treatment ( p ‐value: 0.001). The erythema index also decreased significantly in both 2 weeks ( p ‐value: 0.001) and 4 weeks ( p ‐value: 0.001) after the treatment. The capillaroscopic pattern of lesions showed a decrease in telangiectasia and a reddish background of skin. No side effects of treatment were experienced by any of the patients.
Conclusion
Oxymetazoline 1% cream was safe and effective in treating mild to moderate facial rosacea. The reduction in the skin's vascularity was also objectively confirmed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
- Worldwide Laser Institute, Dallas, Texas, USA.
- Clinical Trial Center, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Aniseh Samadi, Saman Ahmad Nasrollahi
Förderung
- Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences
Zitieren
APA
Sajdeh, F., Samadi, A., Naeimifar, A., Yazdanparast, T., Ahmadi, M., Amiri, F., Kassir, M., Firooz, A., & Nasrollahi, S. A. (2025). Efficacy and Safety of Oxymetazoline 1% Cream for the Treatment of Mild to Moderate Facial Rosacea. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16782
Vancouver
Sajdeh F, Samadi A, Naeimifar A, Yazdanparast T, Ahmadi M, Amiri F, et al. Efficacy and Safety of Oxymetazoline 1% Cream for the Treatment of Mild to Moderate Facial Rosacea. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.16782
BibTeX
@article{Sajdeh2025,
author = {Sajdeh, Fatemeh and Samadi, Aniseh and Naeimifar, Atefeh and Yazdanparast, Taraneh and Ahmadi, Maryam and Amiri, Fatemeh and Kassir, Martin and Firooz, Alireza and Nasrollahi, Saman Ahmad},
title = {Efficacy and Safety of Oxymetazoline 1% Cream for the Treatment of Mild to Moderate Facial Rosacea},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.16782}
}
EUVIMED